PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme
PTC Therapeutics is buying a medicine program (ST-920) for Fabry disease, paying $111 million now and possibly up to $100 million more if it gets approved by regulators. This shows PTC is betting on a new treatment and using skills it already has to bring it to patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.